Bellevue Asset Management’s AYTU BioPharma AYTU Stock Holding History

Bellevue Asset Management’s Portfolio AYTU Stock Details AYTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$53.8K	Hold	25,013	–	–	0.02%	161
2026 Q1	$68.3K	Hold	25,013	–	–	0.03%	132
2025 Q4	$65K	Buy	+25,013	New	+$56.1K	0.02%	131
2021 Q3	–	Sell	-13	Closed	-$1K	–	582
2021 Q2	$1K	Hold	13	–	–	﹤0.01%	560
2021 Q1	$2K	Hold	13	–	–	﹤0.01%	555
2020 Q4	$2K	Hold	13	–	–	﹤0.01%	573
2020 Q3	$3K	Hold	13	–	–	﹤0.01%	470
2020 Q2	$4K	Buy	+13	New	+$3.94K	﹤0.01%	415

Other funds holding AYTU

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Crown Advisors Management Larkspur, California $182M AUM 103.97% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Bellevue Asset Management's AYTU Position: Q2 2026 in Review

Bellevue Asset Management held its AYTU BioPharma (AYTU) position steady in Q2 2026 at 25,013 shares worth $53.8K. The position accounts for 0.02% of the portfolio, ranked #161.

Bellevue Asset Management first reported a position in AYTU in Q2 2020 and has held it in 8 quarters since. The position peaked at $68.3K in Q1 2026. 38 funds tracked by Wall St. Rank hold AYTU as of Q2 2026.

Bellevue Asset Management held 25,013 shares of AYTU BioPharma worth $53.8K as of Q2 2026.
Bellevue Asset Management left its AYTU BioPharma share count unchanged in Q2 2026.
AYTU BioPharma made up 0.02% of Bellevue Asset Management's portfolio in Q2 2026, its #161 holding.
Bellevue Asset Management first reported a position in AYTU BioPharma in Q2 2020 and has held it in 8 quarters since.
Bellevue Asset Management's AYTU BioPharma position peaked at $68.3K in Q1 2026.
38 funds tracked by Wall St. Rank held AYTU BioPharma as of Q2 2026.

Based on Bellevue Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.